Publication Controls Sample Clauses

Publication Controls. To the extent that the J&J Pharmaceutical Affiliates engage HCPs or HCIs as authors for articles or other publications relating to Research (Publications), such HCPs or HCIs shall be referred to as “Authors”. The J&J Pharmaceutical Affiliates implemented prior to the Effective Date, and shall continue to maintain throughout the term of this CIA, Compliance Controls for Publications. The J&J Pharmaceutical Affiliates represent that these controls ensure, among other factors, that: (i) prior to beginning the drafting of a Publication manuscript, Authors confirm in writing that they will participate in a manner consistent with the J&J Pharmaceutical Affiliates’ requirements for Authors; (ii) during the Final Publication Approval process, Publications are reviewed and approved by noncommercial personnel of the J&J Pharmaceutical Affiliates with relevant expertise prior to submission to a journal or congress; (iii) Publications are developed in a transparent and collaborative manner in accordance with principles of scientific exchange; (iv) with certain limited exceptions, no compensation is paid to Authors for their time spent drafting or revising Publications; and
Sample 1Sample 2
AutoNDA by SimpleDocs
Publication Controls. To the extent that Amgen engages HCPs or HCIs as authors for articles or other publications relating to Research involving Government Reimbursed Products (Publications), such HCPs or HCIs shall be referred to as “Authors”. Amgen implemented prior to the Effective Date, and shall continue to maintain throughout the term of this CIA, Compliance Controls for Publications. Amgen represents that these controls ensure, among other factors, that: (i) prior to beginning the drafting of a Publication manuscript, Authors confirm in writing that they will participate in a manner consistent with Amgen’s requirements for Authors; (ii) during the Final Publication Approval process, Publications are reviewed and approved by non- commercial Amgen personnel with relevant expertise prior to submission to a journal or congress; (iii) Publications are developed in a transparent and collaborative manner in accordance with principles of scientific exchange; (iv) with certain limited exceptions, no Corporate Integrity Agreement Amgen Inc. compensation is paid to Authors for their time spent drafting or revising Publications; and
Sample 1
Publication Controls. To the extent that Baxano Surgical engages HCPs or HCIs as authors for articles or other publications relating to research involving Government Reimbursed Products (Publications), such HCPs or HCIs shall be referred to as “Authors.” Within 120 days after the Effective Date, Baxano Surgical shall establish compliance controls for publications. These controls shall ensure, among other factors, that: (i) prior to the beginning of drafting a Publication manuscript, Authors confirm in writing that they will participate in a manner consistent with Baxano Surgical’s requirements for Authors; (ii) during the Final Publication Approval process, Publications are reviewed and approved by non-commercial Baxano Surgical personnel with relevant expertise prior to submission to a journal or congress; (iii) Publications are developed in a transparent and collaborative manner in accordance with principles of scientific exchange; (iv) with certain limited exceptions, no compensation is paid to Authors for their time spent drafting or revising Publications; and (iv) Authors confirm that they satisfy International Committee of Medical Journal Editors (ICMJE) authorship criteria, including providing final approval of the version of the Publication to be published (collectively, “Publication Control”).
Sample 1

Related to Publication Controls

  • Internal Controls The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

  • Disclosure Controls The Company and its subsidiaries maintain an effective system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiaries have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.

  • Access Controls a. Authorized Access - DST shall have controls that are designed to maintain the logical separation such that access to systems hosting Fund Data and/or being used to provide services to Fund will uniquely identify each individual requiring access, grant access only to authorized personnel based on the principle of least privileges, and prevent unauthorized access to Fund Data.

  • Agreement Controls In the event that any term of any of the Loan Documents other than this Agreement conflicts with any express term of this Agreement, the terms and provisions of this Agreement shall control to the extent of such conflict.

  • Internal Control Effective control and accountability must be maintained for all cash, real and personal property, and other assets. Grantee must adequately safeguard all such property and must provide assurance that it is used solely for authorized purposes. Grantee must also have systems in place that provide reasonable assurance that the information is accurate, allowable, and compliant with the terms and conditions of this Agreement. 2 CFR 200.303.

  • Exchange Controls As a condition to this grant of Units, the Employee agrees to comply with any applicable foreign exchange rules and regulations.

  • Internal Control Over Financial Reporting and Internal Accounting Controls The Company maintains (i) effective internal control over financial reporting as defined in Rules 13a-15 and 15d-15 under the Exchange Act, and (ii) a system of internal accounting controls sufficient to provide reasonable assurance that (A) transactions are executed in accordance with management’s general or specific authorizations; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; (C) access to assets is permitted only in accordance with management’s general or specific authorization; and (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

Time is Money Join Law Insider Premium to draft better contracts faster.